of $7.8 million for the year ended December 31, 2007. This charge is
included in Other Income (Expense) in our Statements of Operations, net
principally against payments received as part of the favourable
settlement of the intellectual property suit filed by deCODE in 2006.
deCODE is a biopharmaceutical company applying its discoveries in human genetics to the development of drugs and diagnostics for common diseases. deCODE is a global leader in gene discovery - our population approach and resources have enabled us to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer, genes that are providing us with drug targets rooted in the basic biology of disease. deCODE is also leveraging its expertise in human genetics and integrated drug discovery and development capabilities to offer innovative products and services in personal genome analysis, DNA-based diagnostics, bioinformatics, genotyping, structural biology, drug discovery and clinical development. deCODE is delivering on the promise of the new genetics.(SM) Visit us on the web at http://www.decode.com; on our diagnostics website at http://www.decodediagnostics.com; and, for our pioneering personal genome analysis service, at http://www.decodeme.com.
Conference Call Information
A conference call, during which deCODE President and CEO Kari
Stefansson and CFO Lance Thibault will discuss the past year's financial
results and operating highlights, will be webcast tomorrow, Thursday, March
13, at 8:00am EDT/12 noon GMT. The webcast can be accessed via the
Investors section of deCODE's website, http://www.decode.com,
|SOURCE deCODE genetics|
Copyright©2008 PR Newswire.
All rights reserved